Trial Profile
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs ODN/Pam2 (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Sponsors Pulmotect
- 01 Dec 2021 Results published in the Media Release
- 01 Sep 2021 Status changed from active, no longer recruiting to completed.
- 14 Jul 2021 Planned number of patients changed from 200 to 217.